Valbiotis SA (FRA:8JD)

Market Cap	23.85M +37.2%
Revenue (ttm)	905.00K +414.2%
Net Income	-9.42M
EPS	-0.47
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	173
Open	0.9910
Previous Close	0.9850
Day's Range	0.9910 - 0.9910
52-Week Range	0.5270 - 1.2860
Beta	n/a
RSI	51.05
Earnings Date	Mar 3, 2026

About Valbiotis

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; and TOTUM-448 for the reduction of hepatic steatosis. The company has a partnership with Leiden University, Vanderbilt University, INAF, CarMeN Laborato...

• Industry: Pharmaceutical Preparations
• Founded: 2014
• Employees: 44
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8JD

Financial Performance

In 2025, Valbiotis's revenue was 905,000, an increase of 414.20% compared to the previous year's 176,000. Losses were -9.42 million, -6.06% less than in 2024.